Opinion EDITORIAL Kaitlin L. Nufer, BBiomedSci; Anthony P. Raphael, PhD; H. Peter Soyer, MD, FACD, FAHMS In this issue of JAMA Dermatology, Lallas et al state that “our melanomas and as such fall short for early-stage “dermoscopi- goal today is to detect melanoma, if possible, before it cally featureless” melanoma, particularly melanoma in situ. becomes invasive.” Given the challenges related to the early These difficult-to-diagnose melanomas highlight a problem- detection of melanoma faced atic shortfall in dermoscopic criteria, making identification by clinicians and patients and diagnosis challenging. Related article alike, this goal can only be The study by Lallas and colleagues addresses the limita- achieved through further tions of current dermoscopy criteria by investigating the accu- improving clinical training of clinicians, allied health care racy of melanoma criteria specifically for the diagnosis of mela- workers, and consumers alike, combined with heightened noma in situ. The authors identified 5 dermoscopic criteria individual awareness and advanced imaging technologies. as positive markers for melanoma in situ compared with com- 1 1 Recentlyatthe2017WorldCongressofMelanomainBrisbane, monly occurring benign pigmented lesions. Lallas et al Australia, Wolfgang Weyers, MD, also commented that in regard believe that implementation of their criteria will have the to the detection of
JAMA Dermatology – American Medical Association
Published: Apr 21, 2018
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud